羟氯喹治疗1期1型糖尿病
研究将273例1期1型糖尿病患者随机分配至羟氯喹组(n=183,每日5 mg/kg,最大400 mg)或安慰剂组(n=90),评估羟氯喹是否延迟或预防进展至2期1型糖尿病,即两种或以上胰岛自身抗体且糖耐量异常。中位随访23.3个月后,试验因无效而提前终止;羟氯喹未延迟进展至2期1型糖尿病,但可减少额外自身抗体的获得及抗GAD和抗胰岛素自身抗体滴度。
要点
- 羟氯喹未延迟1期1型糖尿病进展至2期1型糖尿病。
- 羟氯喹组无安全性问题,包括年度眼科检查。
- 羟氯喹减少抗GAD和抗胰岛素自身抗体滴度及额外自身抗体的获得。
核心结论
- 羟氯喹不能延迟1期1型糖尿病个体进展至2期1型糖尿病。
- 药物治疗可减少额外自身抗体的获得以及抗GAD和抗胰岛素自身抗体的滴度。
研究设计与样本
- 随机对照试验,将273例1期1型糖尿病个体随机分配至羟氯喹组(n=183;每日5 mg/kg,最大400 mg)或安慰剂组(n=90)。
主要发现
- 中位随访23.3个月后,试验因无效被数据安全监测委员会提前终止。
- 羟氯喹组无安全性问题,包括年度眼科检查。
- 预设次要分析显示,羟氯喹组在6个月时口服葡萄糖耐量试验的葡萄糖平均曲线下面积出现暂时性下降。
- 羟氯喹组抗GAD和抗胰岛素自身抗体滴度降低,且额外自身抗体的获得减少(P=0.032)。
局限性
- 试验因无效被数据安全监测委员会提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Innate immune responses may be involved in the earliest phases of type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: To test whether blocking innate immaune cells modulated progression of the disease, we randomly assigned 273 individuals with stage 1 T1D to treatment with hydroxychloroquine (n = 183; 5 mg/kg per day to a maximum of 400 mg) or placebo (n = 90) and assessed whether hydroxychloroquine treatment delayed or prevented progression to stage 2 T1D (i.e., two or more islet autoantibodies with abnormal glucose tolerance). RESULTS: After a median follow-up of 23.3 months, the trial was stopped prematurely by the data safety monitoring board because of futility. There were no safety concerns in the hydroxychloroquine arm, including in annual ophthalmologic examinations. Preplanned secondary analyses showed a transient decrease in the glucose average area under the curve to oral glucose in the hydroxychloroquine-treated arm at month 6 and reduced titers of anti-GAD and anti-insulin autoantibodies and acquisition of positive autoantibodies in the hydroxychloroquine arm (P = 0.032). CONCLUSIONS: We conclude that hydroxychloroquine does not delay progression to stage 2 T1D in individuals with stage 1 disease. Drug treatment reduces the acquisition of additional autoantibodies and the titers of autoantibodies to GAD and insulin.
引用
- Libman I, Bingley PJ, Becker D, et al. Hydroxychloroquine in Stage 1 Type 1 Diabetes. Diabetes Care. 2023. PMID: 37708415. doi:10.2337/dc23-1096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。